Latest Regulatory Uncertainty News

The Takeovers Panel has declined to investigate Skin Elements Limited's allegations of undisclosed investor associations following a $2.5 million placement, after 62 Capital agreed to waive transfer restrictions on placement securities.

Elsight has secured a follow-on US$2 million order from a U.S. public safety customer, quadrupling its initial purchase and underscoring growing commercial traction ahead of expected FAA drone rule changes.

Tetratherix Limited secures $15 million via institutional placement plus a capped $2 million share purchase plan at a 14% discount, aiming to fast-track manufacturing expansion and commercial partnerships.

Bremworth Limited reiterates confidence in its Floorscape acquisition scheme despite ongoing regulatory uncertainty, signalling readiness to explore alternatives if the New Zealand Commerce Commission declines clearance.

Zimplats acknowledges Zimbabwe’s classification of platinum group metals as critical minerals and commits to working with the government to navigate the new policy framework while supporting local value addition.

General Capital Limited reported an 18% increase in revenue to $26.8 million for the year ended March 2026, while net profit after tax held steady at $2.7 million amid economic uncertainty and a goodwill impairment. The company declared a fully imputed final dividend, signalling confidence despite regulatory challenges.

Strickland Metals (ASX:STK) has confirmed no hidden material information explains recent share price swings, attributing volatility to regulatory delays in Serbia and broader gold sector weakness.

Pacific Edge edges closer to a Medicare breakthrough with a draft Local Coverage Determination proposing coverage for its Cxbladder Triage and Triage Plus tests, potentially unlocking reimbursement for over 66 million US patients.

The Takeovers Panel has declined Atlas Arteria’s bid to block Diamond Infraco from dispatching its takeover Bidder’s Statement, prolonging uncertainty over the contested offer.

Bioxyne expands its LATAM footprint by securing the first international medicinal cannabis flower supply agreement in Costa Rica, with initial shipments valued over $500,000 planned before June 2026.

Neuren Pharmaceuticals saw a 20% jump in Q1 2026 DAYBUE net sales to US$101 million, with royalties up 23%. The Japan trofinetide trial has been fast-tracked, and the new powder formulation DAYBUE STIX gains early traction.

PYC Therapeutics has dosed the first patient in its Phase 1b trial of PYC-003, targeting Polycystic Kidney Disease, aiming to establish safety and efficacy markers ahead of registrational studies.